<code id='E85ED02DC9'></code><style id='E85ED02DC9'></style>
    • <acronym id='E85ED02DC9'></acronym>
      <center id='E85ED02DC9'><center id='E85ED02DC9'><tfoot id='E85ED02DC9'></tfoot></center><abbr id='E85ED02DC9'><dir id='E85ED02DC9'><tfoot id='E85ED02DC9'></tfoot><noframes id='E85ED02DC9'>

    • <optgroup id='E85ED02DC9'><strike id='E85ED02DC9'><sup id='E85ED02DC9'></sup></strike><code id='E85ED02DC9'></code></optgroup>
        1. <b id='E85ED02DC9'><label id='E85ED02DC9'><select id='E85ED02DC9'><dt id='E85ED02DC9'><span id='E85ED02DC9'></span></dt></select></label></b><u id='E85ED02DC9'></u>
          <i id='E85ED02DC9'><strike id='E85ED02DC9'><tt id='E85ED02DC9'><pre id='E85ED02DC9'></pre></tt></strike></i>

          entertainment

          entertainment

          author:hotspot    Page View:1
          Adobe

          You’re reading the web version of Health Care Inc., STAT’s weekly newsletterfollowing the flow of money in medicine. Sign upto get it in your inbox every Monday.

          Always watch the courts

          There’s a joke that all reporters essentially are legal reporters. But it’s kind of true, especially within the health care beat.

          advertisement

          Congress can’t get anything done, and the federal agencies have their routine rule-making powers. But new, powerful business and health policy decisions get made in the courts — where companies, lobbying groups, and coalitions of people take the time and money to hire attorneys and fight for something that, ultimately, will benefit them financially.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more
          JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc
          JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

          InhonorofJPMWeek,you’rereadingaspecialeditionofourbiotechnewsletter,TheReadout.Tostayontopofthelates

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

          BristolCEOChristopherBoernerBusinessWireviaAPSANFRANCISCO— ChristopherBoernerhasbeentheCEOofBristolM